Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 1, 2000, Pages 35-43

  Sellers, Edward M ^a,b   Kaplan, Howard L ^a,b   Tyndale, Rachel F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; CYTOCHROME P450 2A6; CYTOCHROME P450 ISOENZYME; METHOXSALEN; NICOTINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOAVAILABILITY; BLOOD LEVEL; BREATH ANALYSIS; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; FEMALE; FIRST PASS EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MALE; METABOLIC INHIBITION; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SMOKING CESSATION; TOBACCO; TOBACCO DEPENDENCE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIMETABOLITES; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; BREATH TESTS; CARBON MONOXIDE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; HUMANS; METHOXSALEN; MIXED FUNCTION OXYGENASES; NICOTINE; NICOTINIC AGONISTS; SINGLE-BLIND METHOD; SMOKING;

EID: 0033866924     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.107651     Document Type: Article

References (40)

1. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine
2. Drug therapy: Pharmacologic aspects of cigarette smoking and nicotine addition
3. Pharmacokinetics of nicotine tartrate after single-close liquid enema, oral, and intravenous administration
4. Nicotine's role in smoking: An analysis of nicotine regulation
5. Nicotine intake and its regulation by smokers
6. Role of human cytochrome P4502A6 in C-oxidation of nicotine
7. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes
8. A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2A genes and identification of variation CYP2A6 alleles
9. Nicotine metabolism defect reduces smoking
10. Human cyctochrome P40IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cyctochrome P450IIE1
11. Cyctochrome P450 2E1 and 2A6 enzymes as major catalysts for metaoblic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes
12. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine α-hydroxylation in human liver microsomes
13. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation
14. How effective is nicotine replacement therapy in helping people to stop smoking
15. Clinical pharmacokinetics of nicotine
16. Stable isotope studies of nicotine kinetics and bioavailability
17. Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking
18. Nicotine delivery, kinetics and abuse liability
19. Clinical pharmacokinetics of methoxsalen and other psoralens
20. Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes
21. Metabolism of coumarin by precision-cut calf liver slices and calf liver microsomes
22. Determination of nicotine and two major metabolites in serum by solid-phase extraction and high-performance liquid chromatography, and high-performance liquid chromatography-particle beam mass spectrometry
23. The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire
24. Genotyping of human cytochrome P450 2A6 (CYP2A6) a nicotine C-oxidase
25. Characterization and PCR-based detection of a CYP2A6 gene deletion found at high frequency in a Chinese population
26. Nicotine gum: Dose-related effects on cigarette smoking and subjective ratings
27. Cytochrome P450 2A6 (CYP2A6) genotype determines nicotine (NIC) kinetics in vivo
28. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes
29. CYP2A6 gene defects and duplications alter objective indices of smoking [abstract]
30. Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation: The Photochemotherapy Follow-Up Study
31. Mechanism-based inactivation of P450 2A6 by furanocoumarins
32. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer
33. Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity
34. Pharmacokinetics and pharmacodynamics of psoralens after oral administration: Considerations and conclusions
35. The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer
36. Identification of selective and specific inhibitors of CYP2A6 [abstract]
37. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes
38. Biotransformation of xenobiotics